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Abstract
Glucose transporter (GLUT) expression and regulation were studied in rat brain endothelial cells in primary culture
(RBEC) and in immortalised RBE4 cells. Immunoblotting analysis showed a low expression of the endothelium-specific
GLUT1 in RBEC and RBE4 cells compared to isolated brain capillaries. RBEC and RBE4 cells also expressed the GLUT3
isoform, whereas it was not present in isolated brain capillaries. No change in GLUT expression was observed in endothelial
cells treated with astrocyte-conditioned medium. However, treatment with conditioned medium obtained from glucose-
deprived astrocytes increased endothelial GLUT1 expression and glucose uptake. These results suggest that astrocytes
submitted to hypoglycaemic conditions may release factor(s) that increase glucose uptake through the blood^brain
barrier. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Glucose is the primary energy substrate for brain
metabolism. Glucose transporter proteins (GLUTs)
mediate the facilitative uptake of glucose into mam-
malian cells. A 55 kDa GLUT1 isoform is responsi-
ble for the passage of glucose across the endothelial
cells of the blood^brain barrier (BBB) [1,2]. A less
glycosylated 45 kDa form of GLUT1 is expressed
throughout the parenchyma, mostly in grey matter
astrocytes [3]. The GLUT3 isoform appears to be the
neurone-speci¢c glucose transporter. Indeed, GLUT3
mRNA and protein have been speci¢cally localised
in neurones in vivo [4] and are expressed in primary
cultured neurones [5]. Though GLUT3 immunoreac-
tivity has also been reported in human and dog mi-
crovessels [6,7], it has never been found in rat micro-
vessels [4,7].
BBB glucose transport has been shown to be
modulated by physiologic factors and altered under
pathophysiological conditions, such as Alzheimer’s
disease, chronic seizures, and brain tumours [8^10].
McCall et al. [11] ¢rst demonstrated in vivo that
chronic hypoglycaemia results in increased glucose
transport to the brain. Upregulation of BBB-
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GLUT1 protein and mRNA expression was shown
to mediate this increased transport [12]. Chronic hy-
perglycaemia/diabetes has been associated with re-
duction of BBB glucose transport and BBB-
GLUT1 expression [13,14]. However, other studies
have reported either no change or even upregulation
of GLUT1 expression [15].
Cell cultures are the main tool for investigating
glucose transporter expression and regulation in
brain cells. However, GLUT1 mRNA level is greatly
reduced when brain capillary endothelial cells are
grown in tissue culture [16]. Studies using bovine
brain endothelial cells have demonstrated that
brain-derived factors are able to modulate the ex-
pression of the BBB-GLUT1 gene [17,18]. Other au-
thors have also concluded that factor(s) released
from glial cells stimulate glucose uptake and
GLUT1 expression in primary cultures of bovine
brain endothelial cells [19,20].
We have previously reported the basic properties
of glucose uptake in an immortalised rat brain endo-
thelial cell line (RBE4). In this cell line GLUT1 pro-
tein expression was found to be regulated by medium
glucose depletion [21]. The purpose of the present
study was to investigate the possible e¡ect of astro-
cyte-conditioned medium on GLUT(s) expression
and activity in rat brain endothelial cells in primary
culture (RBEC) and in RBE4 cells.
2. Materials and methods
2.1. Chemicals
Foetal calf serum (FCS) and media were obtained
from Life Technologies (Cergy Pontoise, France).
Rat tail type I collagen, bFGF, geneticin G418 and
dispase were obtained from Boehringer Mannheim
(France). Collagenase CLS3 was obtained from Wor-
thington (Serlabo, Bonneuil sur Marne, France).
DMEM-base without glucose, BSA and DNase I
were obtained from Sigma (St Quentin Fallavier,
France). Electrophoresis reagents, 3-O-[3H]methyl-
D-glucose (5 Ci/mmol) and L-[14C]glucose (55 mCi/
mol) were from Amersham (Les Ulis, France). All
other reagents were from Sigma, unless otherwise
speci¢ed.
2.2. Cell isolation and culture
2.2.1. Primary culture of rat brain capillary
endothelial cells
Brain capillary fragments were isolated from three
2^3-month-old Sprague^Dawley rats as previously
described [22]. Brie£y, cortical grey matter dissected
free of meninges was incubated for 1 h in a collage-
nase/dispase solution plus DNase I and NK-p-tosyl-L-
lysine chloromethyl ketone (TLCK). The homoge-
nate was then centrifuged in 25% bovine serum albu-
min (BSA) and the capillary fraction was incubated
for 3 h in the collagenase/dispase solution. Finally,
the capillaries were puri¢ed by ¢ltration through a 10
Wm pore nylon mesh and then plated out on type I
collagen-coated 35 mm culture dishes in culture me-
dium (Ham’s F10 with glutamax containing 16%
plasma-derived bovine serum (First Link, UK), 80
Wg/ml heparin, 50 Wg/ml gentamicin and 75 Wg/ml
ECGS). Cultures were maintained in humidi¢ed 5%
CO2/95% air at 37‡C. After 3 days, contaminating
pericytes surrounding endothelial cell colonies were
removed with a modi¢ed glass Pasteur pipette under
the microscope. Experiments were performed on con-
£uent once-passaged 3-week-old cultures.
2.2.2. RBE4 cell line
RBE4 immortalised rat brain microvessel endothe-
lial cells [23] were plated on rat tail collagen I-coated
plates and maintained in KMEM/Ham’s F10 (1:1 v/
v) with glutamax containing 10% heat-inactivated
FCS, 300 Wg/ml geneticin (G418) and 1 ng/ml basic
¢broblast growth factor (bFGF) in humidi¢ed 5%
CO2/95% air at 37‡C.
2.2.3. Rat astrocytes
Primary cultures of astrocytes were prepared from
the cerebral cortex of three newborn rats. After re-
moving meninges, the brain tissue was forced gently
through a nylon sieve. Astrocytes were plated at a
concentration of 1.2U105 cells/ml in 75 cm2 £asks in
KMEM/Ham’s F10 (1:1 v/v) with glutamax contain-
ing 10% FCS and 100 Wg/ml gentamicin. Two weeks
after seeding, astrocytes were puri¢ed by overnight
shaking at 37‡C, and treatment with cytosyl arabino-
side and 3-estermethylleucine according to the meth-
od of Meyer et al. [24]. Three weeks after seeding,
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astrocytes were used for preparation of astrocyte-
conditioned medium.
2.2.4. Astrocyte-conditioned medium (ACM)
ACM was obtained by incubating 3^5-week-old
con£uent astrocytes for 48 h in serum-free medium
supplemented with 2 mM glutamine and 100 Wg/ml
gentamicin. ACM was obtained from astrocytes ex-
posed to di¡erent levels of glucose medium. DMEM-
base without glucose containing 1 mM pyruvate was
used, supplemented or not with di¡erent glucose con-
centrations obtained as follows:
b 0 mM ACM with astrocytes cultured in glucose-
free medium,
b 5.5 mM ACM with astrocytes cultured in 5.5 mM
control-glucose medium,
b 25 mM ACM with astrocytes cultured in 25 mM
glucose medium.
To ensure that observed results were not due to
glucose depletion of ACM during the conditioning
process, the glucose level in ACM was measured us-
ing a diagnostic kit (Sigma, kit cat. No. 115-A) and
then adjusted to the initial value before endothelial
cell treatment. After the conditioned medium was
collected, it was ¢ltered on 0.22 Wm ¢lters and stored
frozen at 320‡C.
For endothelial cell treatment, the medium was
changed to a 1:1 (v/v) mixture of standard endothe-
lial cell culture medium and ACM. As ACM was
prepared with serum-free medium, the serum concen-
tration in endothelial cell culture medium was
changed from 10% to 5%, 24 h before treatment
with ACM. This change in serum concentration did
not a¡ect GLUT1 or GLUT3 expression (data not
shown).
2.2.5. Heat treatment, enzymic proteolysis and
ultra¢ltration of ACM
ACM was subjected either to heat exposure (95‡C
for 30 min) or to trypsinisation (2 mg/ml trypsin for
30 min at 37‡C), followed by inactivation of the pro-
tease (2 mg/ml soybean trypsin inhibitor for 1 h at
37‡C). Ultra¢ltration was performed through Centri-
plus YM-10 and YM-3 (Amicon, Millipore)
(3000Ug at 37‡C) membranes that retain molecules
of apparent molecular mass greater than 10 000 Da
and 3000 Da, respectively.
2.2.6. Western blot analysis
Protein fractions were prepared from homogenised
rat brain cortex free of meninges, isolated brain
capillaries and cell monolayers by solubilisation in
20 mM Tris bu¡er pH 7.4 containing 1 mM dithio-
threitol, 1% Triton X-100 and a protease inhibitor
cocktail (Boehringer Mannheim), as previously de-
scribed [22]. Protein samples were separated by elec-
trophoresis on a 10% SDS^polyacrylamide gel and
transferred to a PVDF membrane. GLUT1 protein
was identi¢ed by probing with a polyclonal rabbit
antiserum (GLUT1-CTA) (1/3000 dilution) [1],
GLUT3 protein was identi¢ed by probing with a
polyclonal rabbit antiserum (ALM3-C) (1/7000 dilu-
tion) [25]. Protein bands were detected by enhanced
chemiluminescence. Controls consisted of pre-ab-
sorption of transporter-speci¢c antisera with their
respective synthetic peptides (40 Wg/ml, 2 h at room
temperature).
2.2.7. ELISA assays of glucose transporters
Cells were grown in collagen-coated 96-well tissue
culture plates. ELISA assays of GLUT1 and GLUT3
protein were performed as previously described
[20,21]. After ¢xation in 4% paraformaldehyde in
Ca2, Mg2-free PBS, permeabilisation in PBS con-
taining 0.05% Triton X-100, and saturation with 5%
goat serum to remove the non-speci¢c absorption of
goat anti-rabbit IgG, cells were incubated with
GLUT1-CTA (1/10 000 dilution) or with ALM3-C
(1/20 000 dilution) overnight at 4‡C. The speci¢city
of the polyclonal rabbit antisera GLUT1-CTA and
ALM3-C had already been demonstrated by Western
blot analysis [1,25]. Cells were then incubated with a
goat anti-rabbit IgG (1/2000) (Dako) conjugated to
HRP. HRP substrate (Sigma fast OPD+Urea HP in
H2O) was then added to each well for absorption
reading at 490 nm (A490). Non-speci¢c absorption
was calculated by incubating anti-IgG in the absence
of the primary antibody. Cell monolayers were then
washed several times with PBS and lysed with 0.5 M
NaOH overnight at 37‡C. Samples were taken for
protein determination using a Bio-Rad detergent-
compatible assay. GLUT expression was expressed
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in A490 per Wg of protein. Because cell monolayers
were carefully washed with PBS before lysis with
NaOH, protein level per well was not modi¢ed by
pre-absorption of cells with 5% goat serum.
2.2.8. Uptake experiments
D-Glucose uptake was measured in 24-well plates
using the non-metabolisable analogue 3-O-methyl-
glucose (3-O-MG), with 3-O-[3H]MG as tracer, as
previously described [21]. L-[14C]Glucose was used
as non-speci¢c uptake marker. Brie£y, cell mono-
layers were preincubated in 1 ml glucose-free bu¡er
(GFB) (150 mM NaCl, 4 mM KCl, 4.2 mM CaCl2,
1.2 mM MgCl2, 0.1% BSA, 1 mM pyruvate, 15 mM
HEPES, pH 7.4) for 30 min at 37‡C. After preincu-
bation, cells were incubated with 0.5 ml GFB con-
taining 5 mM 3-O-MG with 3-O-[3H]MG (1 WCi/ml)
and L-[14C]glucose (0.2 WCi/ml). After 30 s, uptake
was rapidly stopped by addition of 2 ml ice-cold
PBS containing 0.25 mM phloretin. Cell monolayers
were washed twice with PBS and then dissolved in
0.1 M NaOH for determination of radioactivity by
L-scintillation counting (Packard model 1900 TR)
and protein quanti¢cation (Bio-Rad). Results are ex-
pressed as 3-O-MG uptake in nmoles per min per mg
of protein.
2.3. Statistical analysis
One-way analysis of variance followed by multiple
comparisons using the Bonferroni adjustment was
performed. In all cases, signi¢cance levels were set
at *P6 0.05, **P6 0.01, ***P6 0.001.
3. Results
3.1. Immunodetection of glucose transporters
With GLUT1-CTA antiserum, GLUT-1 was de-
tected in total rat brain homogenate at a molecular
mass of 45 kDa (Fig. 1a left, lane 1), corresponding
to the low molecular mass GLUT1 isoform expressed
in brain parenchyma. As previously described [1], the
Fig. 1. Immunodetection of GLUT1 and GLUT3. Membranes were probed with GLUT1-CTA antiserum (a, left) or GLUT1-CTA
preabsorbed with 40 Wg/ml synthetic peptide (a, right) or with ALM3-C antibody (b, left) or ALM3-C preabsorbed with 40 Wg/ml syn-
thetic peptide (b, right). Protein samples underwent SDS^PAGE and were transferred to a PVDF membrane: lane 1, 25 Wg brain ho-
mogenate; lane 2, 5 Wg isolated capillaries ; lane 3, 25 Wg RBEC; lane 4, 25 Wg RBE4.
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endothelium-speci¢c high molecular mass GLUT1
isoform was detected in rat brain isolated capillaries
with a molecular mass of 55 kDa (Fig. 1a left, lane
2). In isolated capillaries, very high endothelium-spe-
ci¢c 55 kDa GLUT1 expression was demonstrated
with only 5 Wg brain capillary protein. 55 kDa
GLUT1 was also detected in primary brain endothe-
lial cells (RBEC) and RBE4 cells (Fig. 1a left, lanes 3
and 4), but at a much lower level than in isolated
brain capillaries. Protein bands detected in rat brain
homogenate, isolated capillaries and endothelial cells
corresponded to GLUT1 expression since detection
was abolished competitively by preincubation of
GLUT1-CTA antiserum with its immunising syn-
thetic peptide (Fig. 1a right).
The speci¢city of ALM3-C antibody to GLUT3
isoform detection has already been demonstrated
[25]. A broad band of around 45^50 kDa was de-
tected in total rat brain homogenate (Fig. 1b left,
lane 1), likely corresponding to brain GLUT3 expres-
sion. No expression of GLUT3 could be demon-
strated in isolated rat brain capillaries (Fig. 1b left,
lane 2), whereas a 45^50 kDa band was detected in
both RBEC and RBE4 cells (Fig. 1b left, lanes 3 and
4). These bands likely corresponded to GLUT3 pro-
tein as detection was abolished by preincubation of
ALM3-C antibody with its immunising synthetic
peptide (Fig. 1b right, lanes 3 and 4).
3.2. E¡ect of D-glucose medium concentration on
GLUT1 and GLUT3 expression
E¡ect of D-glucose medium concentration on total
cellular GLUT1 and GLUT3 expression in con£uent
RBEC and RBE4 cells was evaluated by ELISA,
using GLUT1-CTA and ALM3-C antisera (Fig. 2).
When brain endothelial cells were cultured in glu-
cose-deprived medium for 48 h, both total cellular
GLUT1 and GLUT3 were signi¢cantly increased
(53% and 45% for GLUT1 in RBEC and RBE4 cells,
respectively; and 31% and 30% for GLUT3 in RBEC
and RBE4 cells, respectively). On the other hand,
when RBEC and RBE4 cells were cultured under
high glucose conditions for 48 h (25 mM as com-
pared with 5.5 mM for controls), no change in total
cellular GLUT1 or GLUT3 was observed.
3.3. E¡ect of astrocyte-conditioned medium treatment
on GLUT1 and GLUT3 expression
GLUT1 and GLUT3 total cellular expression was
measured by ELISA in RBE4 and RBEC cells
treated with serum-free ACM obtained from astro-
cytes exposed to di¡erent glucose medium levels for
48 h (Fig. 3). To ensure that the observed results
were not due to glucose depletion of ACM during
Fig. 2. E¡ect of glucose medium concentration on GLUT1
(top) and GLUT3 (bottom) expression in RBEC and RBE4
cells. The amount of total cellular GLUT1 and GLUT3 was de-
termined by ELISA using GLUT1-CTA antiserum and ALM3-
C antibody. Endothelial cells cultured for 48 h under control-
glucose conditions (5.5 mM), glucose-starved conditions, or
high-glucose conditions (25 mM) were ¢xed, permeabilised, and
GLUT1-CTA antiserum (1/10 000) or ALM3-C antibody (1/
20 000) was added and colorimetric analysis performed using a
HRP substrate. Data are expressed as optical density values at
490 nm (A490) per Wg of protein. Values represent means þ
S.E.M. (n = 8) of one representative experiment. **P6 0.01.
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the conditioning process, the glucose level in ACM
was measured and adjusted to 5.5 mM before treat-
ing the endothelial cells. Whereas no change in either
GLUT1 or GLUT3 total expression was observed
when RBE4 cells were treated with 5.5 mM ACM
or 25 mM ACM, treatment with 0 mM ACM in-
duced a signi¢cant increase in GLUT1 cellular ex-
pression in both RBEC and RBE4 cells (60% and
52% respectively) (Fig. 3). This e¡ect was speci¢c
to GLUT1 as no change was observed for total
GLUT3 expression. The time response of RBE4 cells
to the application of 0 mM ACM was determined.
No e¡ect of 0 mM ACM was observed after a short
treatment (1 or 4 h). A signi¢cant e¡ect of 0 mM
ACM on GLUT1 expression in RBE4 cells was ob-
served after 24 h treatment, the maximal e¡ect being
observed after 48 h treatment (Fig. 4). These results
suggest that astrocytes cultivated under hypoglycae-
mic conditions may release factor(s) capable of in-
ducing a speci¢c increase in GLUT1 protein expres-
sion in brain endothelial cells.
Active factors present in 0 mM ACM appeared
resistant to heat and proteolytic degradation by tryp-
sin (100% e⁄cacy after 95‡C for 30 min or 2 mg/ml
trypsin for 30 min) (data not shown). Ultra¢ltration
of 0 mM ACM using membranes with molecular
mass cuto¡s of 10 000 Da and 3000 Da produced
low molecular mass ¢ltrates that were also able to
induce a signi¢cant increase in total GLUT1 expres-
sion in RBE4 cells (data not shown). These results
suggest that the soluble factor(s) secreted by astro-
Fig. 4. Time-dependent e¡ect of 0 mM MCA treatment on
GLUT1 total cellular expression in RBE4 cells. RBE4 cells
were treated for various times, with a 1:1 v/v mixture of 5.5
mM medium containing 5% FCS and 0 mM MCA obtained
from astrocytes cultured for 48 h in serum-free medium without
glucose. 0 mM MCA was adjusted to 5.5 mM d-glucose before
endothelial cell treatment. Control cells were cultured in 5.5
mM medium containing 5% FCS. ELISA assay of total
GLUT1 expression was performed and results expressed as op-
tical density values at 490 nm (A490) per Wg of protein. Values
represent means þ S.E.M. (n = 8) of one representative experi-
ment. *P6 0.05; **P6 0.01.
Fig. 3. E¡ect of serum-free ACM treatment on GLUT1 (top)
and GLUT3 (bottom) expression in RBEC and RBE4 cells. En-
dothelial cells were treated for 48 h with a mixture (1:1, v/v) of
5.5 mM D-glucose medium containing 5% FCS with 5.5 mM
ACM obtained from astrocytes cultured in 5.5 mM glucose me-
dium, or with 0 mM ACM obtained from astrocytes cultured
in 0 mM glucose medium, or with 25 mM ACM obtained from
astrocytes cultured in 25 mM glucose medium. Prior to endo-
thelial cell treatment, glucose concentration in ACM was mea-
sured and adjusted to initial values. ELISA assay of GLUT1
and GLUT3 total cellular expression was performed using
GLUT1-CTA antiserum and ALM3-C antibody. Values repre-
sent means þ S.E.M. (n = 8) of one representative experiment.
*P6 0.05; **P6 0.01.
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cytes cultured under hypoglycaemic conditions have
a molecular mass less than 3000 Da.
3.4. E¡ect of 0 mM ACM treatment on 3-O-MG
uptake by brain endothelial cells
Treatment of RBEC and RBE4 cells with 0 mM
ACM resulted in a signi¢cant increase in 3-O-MG
uptake. After 48 h treatment, 85% maximum en-
hancement was measured for RBEC (data not
shown) and 69% maximum enhancement for RBE4
cells (Fig. 5). The e¡ect of 0 mM ACM was signi¢-
cant only after 24 h treatment, whereas no e¡ect was
observed with shorter treatment (1 or 4 h).
RBE4 cells were treated with cycloheximide at the
concentration of 0.05 Wg/ml, which had already been
tested in our previous study on glucose transport
characterisation in RBE4 cells [21]. This study
showed that treatment of RBE4 cells with 0.05 Wg
cycloheximide does not alter cell viability. No in-
crease in 3-O-MG uptake was observed when
RBE4 cells were incubated with 0.05 Wg/ml cyclohex-
imide during 0 mM ACM treatment. This result sug-
gests that protein synthesis is required for stimula-
tion of glucose uptake. 10 000 Da and 3000 Da low
molecular mass 0 mM ACM ¢ltrates were as e¡ective
as non-¢ltered 0 mM ACM at increasing glucose
analogue uptake in RBEC and RBE4 cells (data
not shown).
4. Discussion
In the present study, we report the expression
of both brain endothelium-speci¢c GLUT1 and
GLUT3 proteins in primary RBEC and immortalised
RBE4 cells. However, whereas GLUT1 was highly
expressed in corresponding isolated capillaries, no
expression of GLUT3 was demonstrated. Whereas
control astrocyte-conditioned medium (5.5 mM
ACM) did not induce any change in GLUT1 or
GLUT3 expression, 0 mM ACM obtained from as-
trocytes cultivated under glucose-deprived conditions
was able to induce a speci¢c increase in GLUT1 ex-
pression and glucose transport activity in both
RBEC and RBE4 cells. Factor(s) responsible for
this regulation were heat- and trypsin-resistant and
had an apparent molecular mass smaller than 3000
Da.
Both RBEC and RBE4 cells expressed the 55 kDa
GLUT1 isoform speci¢c for brain endothelium in
vivo. However, this expression was much lower
than in corresponding isolated capillaries re£ecting
the in vivo situation. This decrease in 55 kDa
GLUT1 expression may be associated with the
downregulation of GLUT1 mRNA reported in bo-
vine brain endothelial cells placed in primary culture
[16]. Such a downexpression of GLUT1 transcript in
brain endothelial cells in culture contrasts with the
general overexpression of GLUT1 mRNA when cells
from peripheral tissues are grown in culture [26].
This change is most probably related to the dedi¡er-
entiation phenomenon occurring in brain endothelial
cells when placed in culture.
We demonstrate that the neurone-speci¢c GLUT3
isoform is expressed in both primary RBEC and
RBE4 cells. However, in accordance with a previous
study [7], no expression of GLUT3 was found in our
isolated rat brain capillary preparation. Thus,
GLUT3 expression in brain endothelial cells in cul-
ture corresponds to an upregulation of a gene that is
not expressed physiologically at the BBB in vivo. The
downregulation of endothelium-speci¢c 55 kDa
GLUT1 is thus accompanied by an upregulation of
GLUT3 isoform in brain endothelial cells in culture.
Such an upregulation of non-speci¢c genes in rat
brain endothelial cells in culture has already been
demonstrated for other genes such as mdr1b and
Mrp1 [27,22].
Fig. 5. Uptake of 3-O-MG in RBE4 cells treated for various
times with 0 mM ACM. 3-O-MG uptake was measured at
37‡C and a concentration of 5.5 mM using 3-O-[3H]MG as
tracer. To determine whether protein synthesis was involved in
0 mM ACM, RBE4 cells were cultured in the presence of 0.05
Wg/ml cycloheximide (cyclo) during ACM treatment. Each value
was expressed as a speci¢c uptake corrected by a non-speci¢c
uptake using L-[14C]glucose. Values represent mean þ S.E.M.
(n = 6) of one representative experiment. **P6 0.01.
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Speci¢city of both antisera was thus con¢rmed in
this study, allowing us to conclude that the increases
in absorption reading at 490 nm (A490) per Wg of
protein, as measured by ELISA, are related to in-
creasing levels of GLUT1 or GLUT3 proteins
when primary antibody GLUT1-CTA or ALM3-C
was used.
Glucose depletion induced an increase in A490 per
Wg of protein in RBEC and RBE4 cells. A previous
report demonstrated an increase in glucose transport
in bovine brain endothelial cells cultured in D-glu-
cose-free medium [28]. However, only GLUT1 ex-
pression was measured and correlated with this in-
crease. Gaposchkin and Garcia [29] also reported an
increase in glucose transport in adrenal and aortic
endothelial cells after glucose starvation. In our
study, the upregulation after glucose starvation of
both brain endothelium-speci¢c GLUT1 and non-
speci¢c GLUT3 may correspond to a general adap-
tive response of cells in culture to decreased glucose
supply.
Neither GLUT1 nor GLUT3 total cellular expres-
sion was changed when primary RBEC and RBE4
cells were cultured under high glucose culture condi-
tions. In vivo studies of the e¡ect of hyperglycaemia/
diabetes on glucose transport and glucose transport-
er expression at the BBB have produced contradic-
tory results. However, Simpson et al. [30] demon-
strated recently that diabetic hyperglycaemia did
not have any e¡ect on brain glucose transport activ-
ity or the 55 kDa GLUT1 protein expression.
Treatment of RBE4 and RBEC cells with condi-
tioned medium obtained from astrocytes cultured in
5.5 mM or 25 mM glucose medium did not induce
any change in glucose transporter expression. How-
ever, treatment with conditioned medium obtained
from astrocytes cultured in glucose-deprived medium
induced a speci¢c increase in GLUT1 expression and
in glucose transport capacity. Increases in 3-O-MG
uptake were slightly higher than increases in GLUT1
protein expression (respectively 85% and 60% for
RBEC, and 69% and 52% for RBE4 cells). We sug-
gest that redistribution of the GLUT1 transporter
from cytosol to plasma membrane together with in-
creased GLUT1 protein expression may account for
enhanced 3-O-MG uptake observed in both RBEC
and RBE4 cells [30].
Several in vivo studies have reported an increase in
brain parenchymal and microvascular GLUT1 after
brain ischaemia (hypoxia/hypoglycaemia) [31^33].
However, these in vivo studies could not distinguish
whether this regulation of glucose transporter expres-
sion in brain endothelium was direct or astrocyte-
mediated. In recent years, astrocytes have emerged
as major components in brain metabolism regula-
tion. A metabolic coupling between neurones and
astrocytes is postulated [34]. Astrocytes have also
been reported to be involved in brain protection
against severe ischaemia (hypoxia/hypoglycaemia)
by releasing several factors such as vascular endothe-
lial growth factor [35], basic ¢broblast growth factor
[36], interleukin-1L [37], excitatory amino acids, and
adenosine [38,39]. In our study, factor(s) released by
glucose-deprived astrocytes which induce an increase
in GLUT1 expression in brain endothelial cells were
shown to be resistant to heat and trypsin treatment,
and to have a molecular mass under 3000 Da. These
factors are thus unlikely to be proteins. Peptides with
a molecular mass above 3000 Da, such as VEGF,
bFGF and IL-1L, which have been shown to be re-
leased by cultured astrocytes following ischaemic-like
insults, are ruled out. The factors are unlikely to be
peptides with a molecular mass under 3000 Da, un-
less the peptide bonds involving the arginine or lysine
carboxyl group sensitive to trypsin are absent. They
are unlikely to be lipids, since the astrocytes were
cultured in a serum and protein-free medium. Lipo-
philic molecules would have had to be trapped by
extracellular proteins of the medium to be released
from the cells into the medium. However, small mol-
ecules, such as adenosine or excitatory amino acids,
may be suggested as candidate factors, since in vitro
adenosine has been shown to mediate the increase in
GLUT1 expression in retinal capillary endothelial
cells [40], and glutamate has been reported to stim-
ulate glucose transport in rat cerebellar granule cells
[41].
A previous study [42] has shown that neither C6
plasma membranes nor C6 cell-conditioned medium
were able to induce changes in the level of GLUT1
mRNA in bovine brain endothelial cells in primary
culture. Our results are in agreement with this ¢nd-
ing, since control 5.5 mM ACM was not able to
induce any increase in GLUT1 expression in RBEC
or RBE4 cells. However, they are not in agreement
with results of Takakura et al. [20] who showed an
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increase in GLUT1 expression in brain endothelial
cells treated with glial-conditioned medium obtained
from glial cells cultured for 9 days in 7.5 mM glucose
medium. In our study, when 5.5 mM glucose me-
dium was used to obtain control conditioned me-
dium, glucose concentration was reduced to zero
after 48 h contact with astrocytes. We suggest that
the previously described upregulation of GLUT1 ex-
pression in brain endothelial cells treated with ACM
obtained after 9 day contact with astrocytes would
rather be a response to factor(s) released into the
medium by astrocytes that were glucose-deprived.
Such an ability of astrocytes to increase glucose up-
take capacity in brain endothelial cells, in response to
increased metabolic demand in brain, would further
con¢rm the major regulatory place of astrocytes in
brain metabolism. This phenomenon could be one of
the components of blood^brain glucose transport
following cerebral ischaemia.
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